Page 1

☐ ㅁ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D.C. 20549 FORM 20 - F REGISTRATION STATEMENT PURSUANT TO SECTION 12 ( b ) OR ( g ) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36187 EVOGENE LTD . ( Exact name of Registrant as specified in its charter ) N / A ( Translation of Registrant's Name Into English ) Israel ( Jurisdiction of incorporation or organization ) 13 Gad Feinstein Street , Park Rehovot , Rehovot P.O.B 4173 , Ness Ziona , 7414002 , Israel ( Address of principal executive offices ) Ofer Haviv President and Chief Executive Officer Telephone : + 972-8-931-1900 Facsimile : + 972-8-946-6724 Email : Ofer.Haviv@evogene.com 13 Gad Feinstein Street , Park Rehovot , Rehovot P.O.B 4173 , Ness Ziona , 7414002 , Israel ( Name , Telephone , E - mail and / or Facsimile number and Address of Company Contact Person ) Securities registered or to be registered pursuant to Section 12 ( b ) of the Act : Title of each class Ordinary shares , par value NIS 0.02 per share Trading symbol ( s ) EVGN Name of each exchange on which registered Nasdaq Stock Market LLC